Evolus/EOLS

$12.73

-0.16%
-
1D1W1MYTD1YMAX

About Evolus

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.

Ticker

EOLS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

David Moatazedi

Employees

279

Headquarters

Newport beach, United States
Website
www.evolus.com

Evolus Metrics

BasicAdvanced
$798M
Market cap
-
P/E ratio
-$1.05
EPS
1.32
Beta
-
Dividend rate
$798M
1.31943
$15.43
$7.07
631K
3.211
2.964
654.102
654.102
-2.9%
-31.06%
-472.61%
-40.14%
3.634
43.051
40.45%
18.05%
52.89%

What the Analysts think about Evolus

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 7 analysts.
75.1% upside
High $27.00
Low $16.00
$12.73
Current price
$22.29
Average price target

Evolus Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-22.09% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$59M
-2.63%
Net income
-$13M
11.02%
Profit margin
-22.09%
14.04%

Evolus Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 14.29%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.19
-$0.16
-$0.12
-$0.09
-
Expected
-$0.19
-$0.17
-$0.07
-$0.11
-$0.05
Surprise
-2.26%
-8.05%
79.1%
-14.29%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Evolus stock?

Evolus (EOLS) has a market cap of $798M as of May 14, 2024.

What is the P/E ratio for Evolus stock?

The price to earnings (P/E) ratio for Evolus (EOLS) stock is 0 as of May 14, 2024.

Does Evolus stock pay dividends?

No, Evolus (EOLS) stock does not pay dividends to its shareholders as of May 14, 2024.

When is the next Evolus dividend payment date?

Evolus (EOLS) stock does not pay dividends to its shareholders.

What is the beta indicator for Evolus?

Evolus (EOLS) has a beta rating of 1.32. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Evolus stock price target?

The target price for Evolus (EOLS) stock is $22.29, which is 76.76% above the current price of $12.61. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Evolus stock

Buy or sell Evolus stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing